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CASE REPORT
We describe a 73-year-old male patient who was
previously healthy. Two months prior to presenting to
our department, the patient noticed a dermatosis
involving the trunk, upper and lower limbs, consisting
of multiple pruriginous patches, infiltrated plaques,
and nodules with an erythematous surface. The
patient did not complain of any additional constitutio-
nal symptoms besides pruritus. There were no com-
plaints of weight loss, anorexia or malaise. 
Physical examination revealed a dermatosis
involving, in a bilateral and symmetrical fashion, the
upper torso, abdomen, and proximal upper and lower
limbs. The dermatosis consisted of roughly annular
patches and plaques, with unequal infiltration, exhibi-
ting an erythematous surface. The lesions were pain-
less on palpation (Figure 1). The examination of
lymph node chains was unremarkable. Palpation of the
abdomen revealed no mass or organomegaly.
Incisional cutaneous biopsy revealed the presen-
ce of diffuse infiltration by intermediate-sized lymphoid
cells, with immunohistochemical expression of CD45,
CD4, CD56, and CD123 and negativity for myelopero-
xidase, CD3, CD2, CD5, and CD7 (Figures 2 and 3). 
Axial tomography of the thoraco-abdominal and pel-
vic regions, blood count, myelogram, bone biopsy, and
immunophenotyping of peripheral and medullary blood
did not reveal evidence of systemic involvement at the time. 
The patient was started on oral prednisolone
therapy (40 mg/day), which led to partial remission of
the cutaneous lesions and pruritus. However, relapse
was observed after the first month of therapy. After six
months of follow-up, the patient still showed an
exclusively cutaneous involvement, but rapid and fatal
progression of the disease occurred after 8 months of
follow-up, resulting in the patient’s death.
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DISCUSSION
Blastic plasmacytoid dendritic cell neoplasm is
a recently classified entity.1 The first cases were descri-
bed in 1994, based on WHO recent diagnostic criteria
for blastic NK-cell tumor.2,3 It is more frequently diag-
nosed in the sixth decade of life, but it may occur at
any age, and it seems to predominate in male patients.
It is a rare neoplasm with a usually aggressive clinical
progression, in spite of the established therapeutic
regimens. Patients with this neoplasm have a mean
survival time of 14 months.2
This neoplasm was formerly known as CD4-
positive/CD56-positive hematodermic neoplasm.3 It
was considered to be originated from a myelomono-
cytic lineage precursor, given the common expression
of the surface antigens CD4, CD5, and CD68, and also
because of the common deletion of 5q. 
Recent studies, however, identified the expres-
sion of another antigen, CD123, bringing it closer to
the immunohistochemical profile of plasmacytoid
dendritic cells. These cells are still very poorly charac-
terized, both biochemically and immunophenotypi-
cally. They are present in small amounts in adult bone
marrow, lymph nodes, tonsils, and blood plasma.4-6
The existence of skin lesions at the time of diag-
nosis is clinically frequent and, most of the time, is the
main reason for the patient to seek clinical observa-
tion.7,8 In the majority of the cases, physical examina-
tion reveals the existence of lymphadenopathies
and/or splenomegaly. More rarely, involvement of the
liver, lungs, eyeballs, and central nervous system may
occur. Rapid progression of the disease is typical, with
increasing number of lesions and progressive systemic
involvement. 
Cutaneous lesions are heterogeneous, erythe-
matous or deep purple papules, plaques, nodules or
tumors that can ulcerate, rarely reaching dimensions
over 10 mm. Laboratory studies usually reveal throm-
bocytopenia, anemia, and more seldom leucopenia or
leukocytosis. At the time of diagnosis, approximately
80% of patients already exhibit medullary involve-
ment.2,9
We stress the importance of this case because of
the rare absence of systemic involvement at the time
of the initial presentation of this entity. ❑
Abstract: Blastic plasmacytoid dendritic cell tumor is a rare, highly aggressive systemic neoplasm for which effective
therapies have not yet been established. We describe a 73-year-old man with multiple nodules and patches emerging
on the trunk and limbs. Lesional skin biopsy revealed a plasmacytoid dendritic cell tumor with dense dermal infiltrate
of tumor cells with blastoid features. No apparent systemic involvement was identified in the initial stage. The patient
was treated with prednisone daily, with notorious improvement of the skin lesions, although no complete remission
was obtained. During the six-month follow-up period, no disease progression was documented, but fatal systemic pro-
gression occurred after that period of time.
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Resumo: A leucemia de células dendríticas plasmocitóides blásticas é uma entidade de classificação recente. Descreve-
se o caso de um homem de 73 anos com dermatose envolvendo manchas, placas infiltradas e nódulos eritematosos na
face anterior do tronco, no dorso e nos membros. A biopsia cutânea revelou presença de infiltração difusa por células
linfóides de tamanho intermediário. A imunocitoquímica permitiu o diagnóstico de neoplasia de células dendríticas
plasmocitóides blásticas. O estadiamento não revelou envolvimento sistêmico na época do diagnóstico. O doente ini-
ciou a terapêutica com prednisolona e apresentou remissão inicial das lesões cutâneas. Posteriormente, observou-se
progressão sistêmica da doença, e o doente veio a falecer.
Palavras-chave: Células dendríticas; Leucemia; Neoplasias
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